Negócios · 26/01/20051 min de leitura
Draft Guidance for Industry on Nonclinical Safety Evaluation of Drug Combinations; Availability
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Nonclinical Safety Evaluation of Drug Combinations." The guidance provides recommendations on nonclinical approaches to support the clinical study and approval of fixed-dose combination products (FDCs), copackaged products, and adjunctive therapies.